Blueprint Medicines Corp. | Mid-cap | Healthcare
$129.46
0.00%
| Blueprint Medicines Stock Comparison:
Blueprint Medicines vs VertexBlueprint Medicines vs RegeneronBlueprint Medicines vs BridgeBio PharmaBlueprint Medicines vs Bio-TechneBlueprint Medicines vs Roivant SciencesBlueprint Medicines vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 149.4M
Gross Profit 146.6M 98.12%
Operating Income -41.1M -27.50%
Net Income 496.0K 0.33%
EPS (Diluted) $0.01

Balance Sheet Metrics

Total Assets 1.2B
Total Liabilities 853.5M
Shareholders Equity 342.1M
Debt to Equity 2.49

Cash Flow Metrics

Operating Cash Flow 13.4M
Free Cash Flow -56.3M

Revenue & Profitability Trend

Blueprint Medicines Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i508.8M249.4M204.0M180.1M793.7M
Cost of Goods Sold i20.2M8.5M17.8M17.9M425.0K
Gross Profit i488.7M240.8M186.2M162.1M793.3M
Gross Margin % i96.0%96.6%91.3%90.0%99.9%
Operating Expenses
Research & Development i341.4M427.7M477.4M601.0M326.9M
Selling, General & Administrative i359.3M295.1M237.4M195.3M157.7M
Other Operating Expenses i--8.9M7.8M-
Total Operating Expenses i700.7M722.9M723.7M804.1M484.6M
Operating Income i-212.0M-482.0M-528.6M-634.2M308.7M
Operating Margin % i-41.7%-193.3%-259.1%-352.2%38.9%
Non-Operating Items
Interest Income i40.7M----
Interest Expense i68.8M----
Other Non-Operating Income174.3M-5.2M-6.9M-9.3M-366.0K
Pre-tax Income i-65.9M-506.0M-552.3M-641.1M314.9M
Income Tax i1.2M968.0K5.2M3.0M1.1M
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.3%
Net Income i-67.1M-507.0M-557.5M-644.1M313.9M
Net Margin % i-13.2%-203.3%-273.2%-357.7%39.5%
Key Metrics
EBITDA i-154.4M-470.4M-516.8M-627.7M315.3M
EPS (Basic) i$-1.07$-8.37$-9.35$-11.01$5.76
EPS (Diluted) i$-1.07$-8.37$-9.35$-11.01$5.59
Basic Shares Outstanding i6285700060558000596420005851800054534000
Diluted Shares Outstanding i6285700060558000596420005851800054534000

Income Statement Trend

Blueprint Medicines Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i102.0M71.3M119.7M209.9M684.6M
Short-term Investments i513.5M639.4M825.3M267.2M187.2M
Accounts Receivable i75.8M42.8M23.5M25.2M7.1M
Inventory i13.6M21.2M29.7M21.8M8.6M
Other Current Assets36.0M33.4M35.0M18.1M22.0M
Total Current Assets i742.7M808.4M1.0B554.0M927.8M
Non-Current Assets
Property, Plant & Equipment i89.9M95.0M97.6M103.3M79.0M
Goodwill i-----
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets59.2M40.9M26.8M19.8M11.1M
Total Non-Current Assets i437.1M240.9M303.3M698.2M790.6M
Total Assets i1.2B1.0B1.3B1.3B1.7B
Liabilities
Current Liabilities
Accounts Payable i6.8M4.7M2.7M8.3M4.4M
Short-term Debt i57.3M42.2M27.4M8.1M7.9M
Current Portion of Long-term Debt-----
Other Current Liabilities-----
Total Current Liabilities i260.8M214.9M183.2M149.8M130.8M
Non-Current Liabilities
Long-term Debt i411.8M290.3M215.0M103.3M81.7M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities6.8M6.2M10.3M3.3M7.2M
Total Non-Current Liabilities i620.4M703.7M652.0M131.7M117.5M
Total Liabilities i881.1M918.6M835.2M281.5M248.3M
Equity
Common Stock i64.0K61.0K60.0K59.0K58.0K
Retained Earnings i-2.4B-2.3B-1.8B-1.3B-631.4M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i298.7M130.6M514.7M970.7M1.5B
Key Metrics
Total Debt i469.1M332.5M242.5M111.4M89.6M
Working Capital i481.9M593.5M863.4M404.3M797.0M

Balance Sheet Composition

Blueprint Medicines Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-67.1M-507.0M-557.5M-644.1M313.9M
Depreciation & Amortization i16.3M11.7M11.7M6.5M6.6M
Stock-Based Compensation i108.9M92.7M99.0M91.6M75.5M
Working Capital Changes i-70.3M-45.4M-46.2M-34.5M-19.2M
Operating Cash Flow i-2.0M-423.7M-493.7M-310.8M383.0M
Investing Activities
Capital Expenditures i-4.6M-16.1M-8.9M-3.1M-3.2M
Acquisitions i-----
Investment Purchases i-966.4M-766.4M-489.7M-655.4M-969.4M
Investment Sales i923.6M1.1B349.4M690.8M538.3M
Investing Cash Flow i-47.5M274.0M-149.5M32.3M-434.2M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i147.0M97.9M137.8M0-
Debt Repayment i----0
Financing Cash Flow i195.4M97.9M553.6M0582.5M
Free Cash Flow i-197.2M-452.9M-511.2M-559.9M383.9M
Net Change in Cash i145.8M-51.7M-89.7M-278.5M531.2M

Cash Flow Trend

Blueprint Medicines Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -120.99
Forward P/E -137.72
Price to Book 24.43
Price to Sales 14.89
PEG Ratio -137.72

Profitability Ratios

Profit Margin -27.70%
Operating Margin -27.50%
Return on Equity -47.71%
Return on Assets -9.75%

Financial Health

Current Ratio 2.80
Debt to Equity 208.50
Beta 0.83

Per Share Data

EPS (TTM) $-2.51
Book Value per Share $5.30
Revenue per Share $8.85

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
bpmc8.4B-120.9924.43-47.71%-27.70%208.50
Vertex 100.4B27.855.8422.77%31.86%8.89
Regeneron 59.0B14.031.9415.34%31.37%9.04
BridgeBio Pharma 9.8B-17.82-5.5036.76%98.25%-1.04
Bio-Techne 7.9B60.873.926.53%10.89%20.99
Roivant Sciences 7.9B1.951.72-3.32%96.86%1.93

Financial data is updated regularly. All figures are in the company's reporting currency.